1Kuga H, Morisaki T, Nakamura K, et al. Interferongamrna suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross talk of Smad pathway in a three-dimensional culture model[J]. Oncogene, 2003, 22 (49) : 7838-7847.
2Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteiase phenotype identifies poor prognosis colorectal cancers[J]. Clin Cancer Res, 2004,10(24) :8229-8234.
3Roeb E, Matem S. Matrix metalloproteinase and colorectal cancers[J]. Med Klim(Munich), 2003, 98(12):763-770.
4Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinase, their tissue inhibitors and colorectal cancers staining[J]. Br J Surg, 2000,87(9):1215-1221.
5Papadopoulou S, Scorilas A, Amogianaki N, et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa[J]. Tummor Biol, 2001,22(6) :383-389.
6Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinase in colorectal cancer progression and metastatis[J]. Biochem Biophys Acta, 2004, 1705(2):69-89.
7Koyma S. Enhanced cell surface expression of matrix metalloproteinase and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma[J]. Dig Dis Sci, 2004,49(10): 1621-1630.
8Morn A, Iniesta P, Garcia-Aranda C, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancers[J]. Oncol Rep, 2005,13( 1 ):115-120.
9Davidson B, Oivant-Horwite V, Lazarovici P, et al. Matrix metalloproteinase (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases(MAPK):co-expression in metastatic serous ovarian sarcinoma[J]. Clin Exp Metastasis, 2003,20(7):621-631.
